SUCCESSFUL PHASE II STUDY EXPANDS THE POTENTIAL FOR EPROTIROME IN DYSLIPIDEMIA TREATMENT

SUCCESSFUL PHASE II STUDY EXPANDS THE POTENTIAL FOR EPROTIROME IN DYSLIPIDEMIA
TREATMENT

Karo Bio has successfully completed a 10 week phase IIb study with eprotirome
given to dyslipidemia patients undergoing treatment with the cholesterol
absorption inhibitor ezetimibe. Eprotirome induced a statistically significant
and clinically relevant lowering of serum LDL-cholesterol, triglycerides and
lipoprotein(a) and was safe and well tolerated. Data show that eprotirome in
combination with ezetimibe can become an important treatment option for patients
with dyslipidemia.

Karo Bio's compound eprotirome is a novel, liver selective, thyroid hormone
receptor agonist with a promising profile for treatment of dyslipidemia. In
previous phase II studies eprotirome, alone or in combination with statins,
induced a significant lowering of LDL-cholesterol in dyslipidemia patients.
Furthermore, eprotirome significantly reduced other important risk factors for
development of cardiovascular disease such as triglycerides and lipoprotein(a),
and was well tolerated. 

The intention with the new phase IIb dose ranging study was to expand the
clinical and commercial potential for eprotirome in dyslipidemia treatment by
exploring whether eprotirome in combination with ezetimibe can serve as an
alternative to statin treatment. Ezetimibe is a well documented cholesterol
absorption inhibitor and thus complements eprotirome well with a different
mechanism of action. 

The study was a placebo controlled, parallel group, double blind, 10 week dose
ranging study in 109 patients. Eprotirome was given once daily in doses of 25,
50, or 100 µg in patients who were on a stable ezetimibe treatment, of 10 mg per
day. Top line data show that there was a statistically significant lowering of
LDL-cholesterol in the range of 15-25 % on top of ezetimibe treatment, which is
in line with previous monotherapy and statin combination studies. Pronounced and
clinically relevant reductions of triglycerides and lipoprotein(a) were also
documented."We have, in three consecutive phase II studies, treated a total of 391 patients
with eprotirome.  The data are consistent and robust across the three studies.
Firstly, the compound has been well tolerated. Secondly, eprotirome induced a
profound lowering of several important risk factors for development of
atherosclerotic cardiovascular diseases.  For the dose range 25-100 µg per day
of eprotirome we observed reduction in serum LDL cholesterol from 14 - 26%,
reduction of triglycerides from 23-44% and reduction of Lp(a) from 22-39%. These
effects were of the same magnitude regardless of whether eprotirome was given as
monotherapy or to patients who were on stable treatment with statins or
ezetimibe. With these phase II results we have built up a strong position for
partner discussions and upcoming phase III studies", says Per Olof Wallström,
President of Karo Bio.



For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer 
Phone: +46 8 608 60 20

Per Otteskog, Senior Vice President 
Phone: +46 8 608 60 18

About dyslipidemia treatment and opportunities for eprotirome
Consequences of atherosclerotic cardiovascular disease such as coronary heart
disease and stroke are major medical problems, and there is a need to develop
improved means to treat these disorders by reducing important risk factors such
as serum LDL-cholesterol, triglycerides and lipoprotein(a).

Statins are a class of compounds that are widely used for treatment of elevated
LDL-cholesterol. The global sales of statins were in the range of USD 15-20
billion in 2007.  In spite of active treatment of high blood lipids with
increasing doses of statins over the last 15 years, and achieving subsequent
reductions of heart disease and stroke by some 30%, the morbidity and mortality
for cardiovascular atherosclerotic disease remain high. The treatment goals for
acceptable LDL-cholesterol levels have been generally lowered over the years,
specifically for high risk patients. Combination therapies have become more
common as it proves difficult to reach the treatment target by one medication
only. Apart from LDL-cholesterol there is a growing awareness that it is
important to lower additional risk factors such as triglycerides and
lipoprotein(a). Recent data indicate that lipoprotein(a) is a risk factor for
heart disease and stroke of the same magnitude as high blood pressure. Until now
there have been limited treatment options for patients with elevated
lipoprotein(a).

Eprotirome has the potential to be used as second-line therapy for patients who
do not reach their treatment goal with statin alone. Due to the combined effect
on LDL-cholesterol and triglycerides, eprotirome may be well suited for the
treatment of mixed dyslipidemia (elevated LDL-cholesterol and triglycerides) and
diabetic dyslipidemia. Further, eprotirome may provide a powerful treatment
option for patients with high levels of lipoprotein(a).


About Karo Bio 
Karo Bio is a drug discovery and development company specializing in nuclear
receptors for the development of novel pharmaceuticals. 

The Company has a project portfolio with innovative molecules that primarily
targets metabolic diseases such as diabetes, atherosclerosis and dyslipidemia.
In all of these areas there are significant market opportunities and a need for
new pharmaceuticals with new mechanisms of action. Karo Bio intends to bring
selected compounds within niche therapeutic areas into late stage clinical
development and, potentially, to the market. In addition to pursuing niche
opportunities, Karo Bio continues to develop compounds aimed at treatment of
broad patient populations to clinical proof of concept before out-licensing.

In addition to the proprietary projects, Karo Bio has three strategic
collaborations with international pharmaceutical companies for development of
innovative therapies for the treatment of common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters:
KARO.ST).

This press release is also available online at: www.karobio.com and
www.newsroom.cision.com